Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Extended Follow-Up of Reduced Intensity Transplantation with an Alemtuzumab-Containing Regimen for Follicular Lymphoma.

Kirsty Thomson, MD, Emma Morris, MD, Donald Milligan, MD, Ann Hunter, MD, Gordon Cook, MD, Adrian Bloor, MD, Charles Craddock, MD, Lynny Yung, MD, Anne Parker, MD, Ronjon Chakraverty, MD, Karl Peggs, MD, Stephen Mackinnon, MD

Blood (2007) 110 (11): 1666.

https://doi.org/10.1182/blood.V110.11.1666.1666

Published: 2007

Journal Articles

Idarubicin and ATRA Is as Effective as MRC Chemotherapy in Patients with Acute Promyelocytic Leukaemia with Lower Toxicity and Resource Usage: Preliminary Results of the MRC AML15 Trial.

Alan K. Burnett, MD, Robert K. Hills, DPhil, David Grimwade, MD, Anthony H. Goldstone, MD, Ann Hunter, MD, Don Milligan, MD, Archie G. Prentice, MD, Nigel H. Russell, MD, Keith Wheatley, DPhil

Blood (2007) 110 (11): 589.

https://doi.org/10.1182/blood.V110.11.589.589

Published: 2007

Journal Articles

De-Escalation of the Alemtuzumab Dose Prior to Nonmyeloablative HLA-Identical Sibling Transplantation: Crucial Role of Timing.

Ronjon Chakraverty, MD, Maria Dimopoulou, MD, Julie Glanville, MD, Kirsty Thomson, MD, Karl Peggs, MD, Donald Milligan, MD, Gordon Cook, MD, Graham Jackson, MD, Anne Parker, MD, Ann Hunter, MD, Nigel Russell, MD, Rachel Pearce, Stephen Mackinnon, MD

Blood (2006) 108 (11): 2901.

https://doi.org/10.1182/blood.V108.11.2901.2901

Published: 2006

Journal Articles

Harvesting for “A Rainy Day”: A Retrospective Analysis of Its Cost-Effectivenes and Ethical Implications.

Miguel Ortin, MD, Sue Bricknell, Jane Kimber, Lynn Stirrup, Dietmar Hofer, MD, Martin J. Dyer, Ann Hunter, MD

Blood (2005) 106 (11): 2924.

https://doi.org/10.1182/blood.V106.11.2924.2924

Published: 2005

Journal Articles

A Retrospective Comparison between Cyclophosphamide (Cy) Followed by G-CSF, and Ifosfamide, Etoposide and Epirubicin (IVE) Plus G-CSF Mobilisation Regimes in Haematological Malignancies.

Miguel Ortin, MD, Sue Bricknell, Sheila Gribben, Lynn Stirrup, Martin Dyer, Ann Hunter, MD

Blood (2005) 106 (11): 5484.

https://doi.org/10.1182/blood.V106.11.5484.5484

Published: 2005

Journal Articles

Reduced Intensity Allogeneic Transplantation for Non-Hodgkin’s Lymphoma: Extended Follow-Up of an Alemtuzumab-Containing Regimen.

Kirsty J. Thomson, MD, Emma C. Morris, MD, Don Milligan, MD, Gordon Cook, MD, Jim Cavet, MD, Charles Craddock, MD, Ann Hunter, MD, Steve Schey, MD, Anne Parker, MD, Anthony H. Goldstone, MD, David C. Linch, MD, Karl S. Peggs, MD, Stephen Mackinnon, MD

Blood (2005) 106 (11): 401.

https://doi.org/10.1182/blood.V106.11.401.401

Published: 2005

Journal Articles

Improved Outcome Following Reduced Intensity Allogeneic Transplantation in Hodgkin’s Lymphoma Relapsing Post-Autologous Transplantation.

Kirsty J. Thomson, MD, Karl S. Peggs, MD, Paul Smith, MSc, Raj Chopra, MD, Jim Cavet, MD, Ann Hunter, MD, Anne Parker, MD, Ruth Pettengell, MD, Don Milligan, MD, Emma C. Morris, MD, Anthony H. Goldstone, MD, David C. Linch, MD, Stephen Mackinnon, MD

Blood (2005) 106 (11): 657.

https://doi.org/10.1182/blood.V106.11.657.657

Published: 2005

NARROW

Extended Follow-Up of Reduced Intensity Transplantation with an Alemtuzumab-Containing Regimen for Follicular Lymphoma.

Idarubicin and ATRA Is as Effective as MRC Chemotherapy in Patients with Acute Promyelocytic Leukaemia with Lower Toxicity and Resource Usage: Preliminary Results of the MRC AML15 Trial.

De-Escalation of the Alemtuzumab Dose Prior to Nonmyeloablative HLA-Identical Sibling Transplantation: Crucial Role of Timing.

Harvesting for “A Rainy Day”: A Retrospective Analysis of Its Cost-Effectivenes and Ethical Implications.

A Retrospective Comparison between Cyclophosphamide (Cy) Followed by G-CSF, and Ifosfamide, Etoposide and Epirubicin (IVE) Plus G-CSF Mobilisation Regimes in Haematological Malignancies.

Reduced Intensity Allogeneic Transplantation for Non-Hodgkin’s Lymphoma: Extended Follow-Up of an Alemtuzumab-Containing Regimen.

Improved Outcome Following Reduced Intensity Allogeneic Transplantation in Hodgkin’s Lymphoma Relapsing Post-Autologous Transplantation.

Email alerts

ASH Publications

American Society of Hematology

Extended Follow-Up of Reduced Intensity Transplantation with an Alemtuzumab-Containing Regimen for Follicular Lymphoma.

Idarubicin and ATRA Is as Effective as MRC Chemotherapy in Patients with Acute Promyelocytic Leukaemia with Lower Toxicity and Resource Usage: Preliminary Results of the MRC AML15 Trial.

De-Escalation of the Alemtuzumab Dose Prior to Nonmyeloablative HLA-Identical Sibling Transplantation: Crucial Role of Timing.

Harvesting for “A Rainy Day”: A Retrospective Analysis of Its Cost-Effectivenes and Ethical Implications.

A Retrospective Comparison between Cyclophosphamide (Cy) Followed by G-CSF, and Ifosfamide, Etoposide and Epirubicin (IVE) Plus G-CSF Mobilisation Regimes in Haematological Malignancies.

Reduced Intensity Allogeneic Transplantation for Non-Hodgkin’s Lymphoma: Extended Follow-Up of an Alemtuzumab-Containing Regimen.

Improved Outcome Following Reduced Intensity Allogeneic Transplantation in Hodgkin’s Lymphoma Relapsing Post-Autologous Transplantation.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only